论文部分内容阅读
目的探讨杜冷丁配伍利凡诺和米非司酮在中期妊娠引产中的应用效果。方法选择2011年1月—2012年12月280例妊娠13~28周健康妇女,随机分为观察组和对照组各140例。两组均羊膜腔注射利凡诺100 mg,当日空腹口服米非司酮50 mg/次,3次/d。观察组发动规律宫缩宫口开大1 cm左右时,一次性肌内注射杜冷丁75 mg。观察两组引产时间、出血量、刮宫情况、引产成功率及不良反应。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组引产时间<3 h34.3%,3~6 h 38.6%,6~12 h 21.4%,12~24 h 4.3%,≥24 h 1.4%;对照组引产时间<3 h 20.7%,3~6 h 10.0%,6~12 h 40.0%,12~24 h 25.0%,≥24 h 4.3%,两组比较差异有统计学意义(P<0.05)。刮宫率观察组14.29%,对照组24.29%,两组比较差异有统计学意义(P<0.05)。结论杜冷丁配伍利凡诺和米非司酮用于中期妊娠引产安全有效,只要加强管理,合理使用,是非常理想的配合引产药物,值得临床推广应用。
Objective To investigate the application effect of dolantin in combination with rivanol and mifepristone in induction of labor during the second trimester of pregnancy. Methods From January 2011 to December 2012, 280 healthy pregnant women, aged from 13 to 28 weeks, were randomly divided into observation group (140 cases) and control group (140 cases). Both groups were injected rivaroxan 100 mg intramuscularly on the day of fasting oral mifepristone 50 mg / time, 3 times / d. Observation group to start the law of contractions uterine opening about 1 cm, a one-time intramuscular injection of pethidine 75 mg. Observation of two groups of induction of labor, bleeding, curettage, induction of labor success rate and adverse reactions. Count data using χ2 test, P <0.05 for the difference was statistically significant. Results In the observation group, the induction time was 34.3%, 38.6% at 3 ~ 6 h, 21.4% at 6 ~ 12 h, 4.3% at 12 ~ 24 h, and 1.4% at 24 h. In the control group, the induction time was 20.7% ~ 6 h 10.0%, 6 ~ 12 h 40.0%, 12 ~ 24 h 25.0%, ≥24 h 4.3%. There was significant difference between the two groups (P <0.05). The curettage rate was 14.29% in the observation group and 24.29% in the control group, with significant difference between the two groups (P <0.05). Conclusion Combination of dolantin and mifepristone is safe and effective for induction of labor during the second trimester pregnancy. It is an ideal combination with induction drugs as long as management is strengthened and rational use is worthy of clinical promotion and application.